Cumberland Pharmaceuticals
Lawton Seal possesses extensive experience in the medical field, currently serving in Field Medical Affairs at Cumberland Pharmaceuticals since April 2019. Prior to this role, Lawton Seal had a long tenure at Smith&Nephew Biotherapeutics / Healthpoint / DPT Labs, spanning from January 1999 to November 2016, where the position of Senior Director of Medical Science was held. While initially based at DPT Laboratories in San Antonio, Lawton Seal relocated to the home office for DFB Pharmaceuticals and Healthpoint, LTD, ultimately leading a team of Medical Science Liaisons with a focus on the pathophysiology of chronic wounds. Lawton Seal holds a Doctor of Philosophy (Ph.D.) in Medical Virology and Microbiology/Immunology from Louisiana State University School of Medicine in Shreveport (1983-1985), and a Master’s Degree from Louisiana State University Health Sciences Center (1973-1977), with a thesis centered on human Herpesviruses and distinguishing markers between HSV 1 and HSV 2.
This person is not in any offices
Cumberland Pharmaceuticals
2 followers
Cumberland Pharmaceuticals is a specialty pharmaceutical company that acquires, develops and commercializes branded prescription products designed to improve quality of care and address unmet medical needs. With a focus on underserved niche markets, including hospital acute care and gastroenterology, they deliver products that serve patients in the U.S. market. Cumberland also makes its products available to patients internationally through select strategic partnerships. They own the worldwide rights to all their brands. While Cumberland’s commercial capabilities are focused on the U.S. market, their business development team is actively pursuing opportunities to make their brands available to patients in markets around the globe. Their primary mission is to improve upon patient care with products that offer clear advantages over existing treatments. They also strive to deliver solutions that may help reduce costs for healthcare providers and, ultimately, patients.